Welcome to our dedicated page for Athersys news (Ticker: ATHX), a resource for investors and traders seeking the latest updates and insights on Athersys stock.
Athersys, Inc. (symbol: ATHX) is a leading clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative medications aimed at addressing significant and life-threatening diseases. The company leverages proprietary technologies to build a robust pipeline featuring highly differentiated, potential best-in-class therapeutics. These developments span multiple disease areas, including both stem cell therapy and pharmaceuticals.
Athersys is pioneering in the field of regenerative medicine with its flagship product, MultiStem®, an investigational stem cell therapy targeting critical conditions such as ischemic stroke, acute respiratory distress syndrome (ARDS), and other inflammatory and immune-mediated diseases. The company’s focus on extending and enhancing the quality of human life is evident through its diverse and strategic therapeutic programs.
Recent achievements include advancing clinical trials for MultiStem® and securing key partnerships that bolster the company’s research, development, and commercialization capabilities. Financially, Athersys remains committed to prudent management of resources, enabling sustained innovation and growth in its therapeutic pipeline.
With a strong emphasis on regulatory compliance, scientific rigor, and patient outcomes, Athersys continues to push the boundaries of medical science. The company’s mission is to deliver transformative therapies that address unmet medical needs, ultimately improving the lives of patients around the world.
For more in-depth and up-to-date information on Athersys, including the latest news and developments, please refer to the sources listed below:
- --- (Insert latest news here) ---
- --- (Insert latest news here) ---
- --- (Insert latest news here) ---
- --- (Insert latest news here) ---
- --- (Insert latest news here) ---
Athersys, Inc. (ATHX) announced positive topline results from the TREASURE ischemic stroke study conducted in Japan, showcasing the potential therapeutic impact of its MultiStem treatment. The study enrolled 206 patients and demonstrated improvements in functional independence, specifically mRS ≤2 and Barthel Index ≥95. Although the primary endpoint did not achieve statistical significance, long-term outcomes indicated continued improvement over one year. Athersys expressed confidence in the future success of its ongoing MASTERS-2 clinical trial.
Athersys, Inc. (NASDAQ: ATHX) announced that CEO Dan Camardo will participate virtually in the H.C. Wainwright Global Investment Conference from May 23-26, 2022, in Miami, Florida. The management team will also hold one-on-one meetings with institutional investors during this time. Interested investors can schedule meetings via provided email contacts. A presentation will be available on-demand starting May 24, 2022, at 7:00 a.m. ET on the Company's website, with an archived replay following the conference.
Athersys announced financial results for Q1 2022, revealing revenues of $2.9 million, up from zero the previous year.
The company's R&D expenses increased to $20.9 million, while G&A expenses significantly decreased to $4.1 million. The net loss narrowed to $22.2 million compared to $26.5 million in Q1 2021.
Athersys received FDA approval for bioreactor-manufactured MultiStem, enhancing production capabilities, and appointed Daniel A. Camardo as CEO. The company anticipates topline data from its TREASURE study in May, hosting a conference call to discuss results.
Athersys, Inc. (Nasdaq: ATHX) will participate in a fireside chat at the Bank of America Securities 2022 Global Healthcare Conference on May 11, 2022, at 4:00 p.m. PT in Las Vegas. CEO Dan Camardo and CFO Ivor Macleod will represent the company. Investors can schedule one-on-one meetings with the management during the conference. A live webcast will be available on the company’s website, with an archived replay accessible afterward. Athersys focuses on developing therapeutic products, notably the MultiStem® cell therapy for various medical conditions.
Athersys, Inc. (NASDAQ: ATHX) will release its Q1 2022 financial results on May 6, 2022, at 8:00 a.m. EDT. This announcement coincides with the upcoming topline data from its partner, HEALIOS K.K., regarding the Phase 2/3 TREASURE study, which evaluates MultiStem® (invimestrocel, HLCM051) for ischemic stroke treatment. Following this data release, Athersys will hold an investor conference call to discuss the results and future implications for its clinical trials.
Athersys announced significant updates regarding its partnership with Healios K.K. for the MultiStem cell therapy. The last 365-day follow-up visit in the Phase 2/3 TREASURE study for ischemic stroke has been completed, marking a key milestone. Topline results are expected in May 2022. Healios is also in discussions with Japan's PMDA regarding the ARDS program, although additional data is required for approval, delaying application plans. Athersys remains optimistic about the potential of MultiStem therapy, evidenced by its ongoing MACOVIA study for ARDS patients.
Athersys, Inc. (NASDAQ: ATHX) announces presentations at two upcoming healthcare conferences: the Locust Walk Stem Cell Conference on April 11, 2022, and the Needham Healthcare Conference on April 13, 2022. President B.J. Lehmann will present on MultiStem®, a cell therapy in late-stage clinical development for ischemic stroke and ARDS. CEO Dan Camardo will outline clinical programs and commercialization strategies. Live webcasts of both events will be available online, with recordings accessible afterward.
Athersys announced its financial results for Q4 and full year 2021, reporting revenues of $5.5 million, a significant increase from $1.4 million in 2020. The company experienced a net loss of $87 million for the year, compared to $78.8 million in the previous year. CEO Dan Camardo highlighted the potential of MultiStem in cell therapy, especially following positive data from clinical trials. The company also strengthened its partnership with Healios, which is critical for regulatory submissions in Japan.
Athersys (NASDAQ: ATHX) appointed Daniel Camardo as CEO, offering him a significant inducement package. He received nonqualified stock options to purchase 10 million shares at an exercise price of $0.86, the closing price of the stock on his start date, February 14, 2022. The options vest in part over four years and relate to company milestones including regulatory approvals and sales achievements. Athersys focuses on biotherapeutic developments, particularly the MultiStem cell therapy, targeting multiple critical care indications.
Athersys, Inc. (NASDAQ: ATHX) will release its Q4 and full year 2021 financial results on
FAQ
What is the market cap of Athersys (ATHX)?
What is Athersys, Inc.?
What is MultiStem®?
What types of therapies is Athersys developing?
What are some recent achievements of Athersys?
What is the financial condition of Athersys?
How does Athersys aim to improve human life?
Where can I find updates on Athersys?
What is the significance of Athersys's therapeutic programs?
Who can benefit from Athersys's therapies?
How does Athersys ensure the quality of its therapies?
